We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current BMRN market cap is 13.23B. The company's latest EPS is USD 0.8806 and P/E is 78.93.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 595.28M | 581.33M | 646.21M | 648.83M | 712.03M |
| Operating Income | 58.87M | 25.66M | 41.92M | 78.46M | 120.45M |
| Net Income | 56.04M | 40.38M | 20.38M | 88.66M | 107.17M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.7B | 1.86B | 1.85B | 2.1B | 2.42B |
| Operating Income | -126.04M | -96.27M | -20.41M | 41.56M | 185.8M |
| Net Income | -23.85M | 859.1M | -2.15M | 141.56M | 167.65M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 6.56B | 6.76B | 6.84B | 6.87B | 7.07B |
| Total Liabilities | 1.78B | 1.86B | 1.89B | 1.8B | 1.78B |
| Total Equity | 4.78B | 4.9B | 4.95B | 5.07B | 5.29B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 4.69B | 5.85B | 6B | 6.38B | 6.84B |
| Total Liabilities | 1.57B | 1.74B | 1.73B | 1.77B | 1.89B |
| Total Equity | 3.12B | 4.11B | 4.27B | 4.6B | 4.95B |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -3.87M | 131.78M | 159.26M | 46.97M | 165.73M |
| Investing | -482k | -46.28M | -111.24M | -14.24M | 76.24M |
| Financing | -28.78M | -29.57M | -18.73M | -42.79M | -30.18M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 48.26M | 85.37M | 304.54M | 175.9M | 159.26M |
| Investing | -31.03M | -53.62M | -366.31M | -20.03M | -111.24M |
| Financing | -74.67M | 181.12M | -48k | -18.65M | -18.73M |
| Market Cap | 13.23B |
| Price to Earnings Ratio | 78.93 |
| Price to Sales Ratio | 5.47 |
| Price to Cash Ratio | 17.52 |
| Price to Book Ratio | 2.67 |
| Dividend Yield | - |
| Shares Outstanding | 190.38M |
| Average Volume (1 week) | 1.26M |
| Average Volume (1 Month) | 2.33M |
| 52 Week Change | -19.64% |
| 52 Week High | 99.56 |
| 52 Week Low | 67.7501 |
| Spread (Intraday) | 8.97 (12.13%) |
| Company Name | BioMarin Pharmaceutical Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.biomarin.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
